SCHEMBL25232158

SCHEMBL25232158

CC(C)(C)OC(=O)N1CCN(c2ccc(-c3nc4c(Cl)ncnc4[nH]3)cc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 2/20 0.49
SMN1; SMN2 Q16637 3/20 0.48
MAPT P10636 2/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
TSHR P16473 1/20 0.48
MAP4K4 O95819 1/20 0.48
TBK1 Q9UHD2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
HTT P42858 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
ALOX5 P09917 1/20 0.46
CCNK O75909 1/20 0.45
CCNA2 P20248 1/20 0.45
CDK2 P24941 1/20 0.45
CCND3 P30281 1/20 0.45
CDK9 P50750 1/20 0.45
CDK6 Q00534 1/20 0.45
CNR1 P21554 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25666779 0.85 DDB1 (0.47) HTTPRMT5NAMPTJAK2JAK3
SCHEMBL16535580 0.82 KIT (0.68) KITSMN1; SMN2MAPTMEN1KMT2A
SCHEMBL17289610 0.78 PARP1 (0.51) TBK1CNR2PRMT5ALKADK
SCHEMBL4820200 0.77 AURKA (0.49) KITSMN1; SMN2MAPTMEN1KMT2A
SCHEMBL13985647 0.77 AURKA (0.51) SMN1; SMN2MAPTMEN1KMT2ATSHR
SCHEMBL13218521 0.77 MAPT (0.54) KITSMN1; SMN2MAPTMEN1KMT2A
SCHEMBL31017638 0.77 ALK (0.53) KITSMN1; SMN2MAPTMEN1KMT2A
SCHEMBL25830774 0.77 ALK (0.53) KITSMN1; SMN2MAPTMEN1KMT2A
SCHEMBL30984061 0.75 HRH4 (0.48) MAP4K4ALDH1A1
SCHEMBL21876057 0.75 MAPT (0.62) SMN1; SMN2MAPTMEN1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116589467-A Degradation of Bruton's Tyrosine Kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligands and methods of use thereof 百济神州有限公司 2023-08-15 CN disclosed
CN-116589466-A Degradation of Bruton's Tyrosine Kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligands and methods of use thereof 百济神州有限公司 2023-08-15 CN disclosed
US-20230167118-A1 DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INIDBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BEONE MEDICINES I GMBH (CH) 2023-06-01 US disclosed
US-20230167118-A1 DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INIDBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BEONE MEDICINES I GMBH (CH) 2023-06-01 US disclosed
US-20230167118-A1 DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INIDBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BEONE MEDICINES I GMBH (CH) 2023-06-01 US disclosed
CN-115485278-A Degradation of Bruton's Tyrosine Kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligands and methods of use thereof 百济神州有限公司 2022-12-16 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167118-A1 DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INIDBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BTK, CBL, SYK KIT 1940/4885SMN1; SMN2 4065/4885MAPT 3942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.